Fat Malabsorption

The clinical impact of fat malabsorption depends on the duration, severity, and primary etiology. Chronic malabsorption leads to inadequate lipid absorption, steatorrhoea, nutrient deficiencies, and progressive weight loss. In paediatric populations, the resulting nutritional insufficiency can impair growth and development, making routine nutritional assessment essential.

• Pancreatic Insufficiency: Reduced exocrine function (e.g., chronic pancreatitis, cystic fibrosis, pancreatic surgery/disorders) decreases pancreatic lipase availability, impairing triglyceride breakdown.
• Hepatobiliary Disorders: Reduced bile production, secretion, or flow (e.g., cholestatic liver disease, biliary obstruction, advanced hepatic disease) prevents micelle formation and elevates the risk of fat-soluble vitamin deficiencies.
• Small Intestinal Disorders: Mucosal damage or reduced surface area (e.g., coeliac disease, Crohn’s disease, chronic infections, and short bowel syndrome) directly compromises nutrient transport.
• Other Causes: Gastrointestinal surgeries, inherited metabolic disorders, and transport defects.

Persistent fat malabsorption directly compromises the status of lipid-soluble nutrients:

• Vitamin A: Critical for vision, immune function, cellular differentiation, and epithelial/mucosal integrity. Deficiency impairs visual acuity and epithelial health.
• Vitamin D: Regulates calcium and phosphate homeostasis, bone mineralisation, and immune function. Paediatric patients are highly vulnerable to skeletal deficits due to growth demands.
• Vitamin E: Serves as a lipid-soluble antioxidant protecting cellular structures. Prolonged deficiency can result in neuromuscular and neurological manifestations.
• Vitamin K: Essential for the post-translational activation of coagulation factors. Inadequate levels impair normal haemostasis.

1. Clinical Assessment

• History: Focus on the duration/character of bowel habits, dietary intake, weight changes, developmental trajectories in children, surgical history (GI/pancreatic), hepatobiliary disease, and medication use.
• Physical Exam: Comprehensive anthropometric and nutritional assessment.

2. Laboratory & Diagnostic Testing

• Screening: CBC, comprehensive metabolic panels, liver function tests, and baseline nutritional markers.
• Vitamin Status: Serum quantification of vitamins A, D, E, and K indicated in established or prolonged malabsorption.
• Absorption Assays: Quantitative faecal fat testing (timed collection during controlled dietary fat intake) to confirm steatorrhoea.
• Targeted Workup: Faecal elastase-1 to evaluate for exocrine pancreatic insufficiency, specialised lipid breath tests, and disease-specific investigations (e.g., serology, endoscopy, or biopsy) guided by the suspected primary pathology.

The management of fat malabsorption requires a dual-targeted framework focused on resolving the primary etiologic pathology and repleting systemic nutritional deficits. Treatment must be precision-tailored to the specific site of digestive breakdown.

• Disease-Specific Interventions: Direct targeting of the primary diagnosis (e.g., a strict gluten-free diet for Celiac Disease, or targeted antibiotics for SIBO).
• Pancreatic Enzyme Replacement Therapy (PERT): Mandatory for exocrine pancreatic insufficiency (EPI). Enteric-coated enzymes must be dosed with all lipid-containing meals to hydrolyze dietary triglycerides.
• Hepatobiliary Optimization: Medical or surgical management of cholestatic disorders or biliary obstructions to restore the luminal bile acid flow required for micellar emulsification.
• Dietary Modifications: Implementation of tailored strategies, such as utilizing Medium-Chain Triglycerides (MCTs), which bypass normal micellar aggregation and absorb directly into the portal circulation.
• Individualised Vitamin Repletion: Micronutrient supplementation must be tailored by the treating clinician. Prescription regimens are adjusted based on the patient's age, severity of malabsorption, serial laboratory findings, and the use of specialized fat-soluble or micellized formulations of vitamins A, D, E, and K to optimize bioavailability across compromised brush borders.

Clinical Overview

Cholestasis is a disorder characterised by the impaired formation, secretion, or flow of bile, leading to the retention of biliary constituents within the liver and their accumulation in systemic circulation. It arises from hepatocyte dysfunction, defective bile transport molecular mechanisms, or physical obstruction within the intrahepatic or extrahepatic biliary system.

Clinically significant cholestasis disrupts intestinal micelle formation by reducing luminal bile acid delivery, impairing the digestion and absorption of dietary lipids and fat-soluble vitamins (A, D, E, and K). In infants, early recognition of conjugated hyperbilirubinaemia is vital to differentiate it from physiological jaundice and to initiate timely, life-saving interventions.

Neonatal Cholestasis & Clinical Significance

Neonatal cholestasis is defined by an elevation of conjugated or direct bilirubin during the neonatal period. Persistent infantile jaundice must not be assumed to be physiological or prolonged unconjugated hyperbilirubinaemia.

• Diagnostic Threshold: Initial evaluation requires total and direct/conjugated bilirubin quantification. A direct bilirubin concentration >1 mg/dL is generally considered abnormal, particularly when total bilirubin is low, and mandates prompt investigation.
• Nutritional Impact: Prolonged lack of intraluminal bile acids causes fat malabsorption, steatorrhoea, essential fatty acid deficiency, and progressive fat-soluble vitamin deficiencies. Infants and children are highly vulnerable, frequently presenting with poor weight gain and severe growth impairment.

Classification & Etiology

Cholestatic disorders are classified based on the anatomical site and mechanism of impaired bile flow:

Pathophysiology & Clinical Manifestations

Cellular & Mechanical Mechanisms

Normal bile flow relies on hepatocyte transporter proteins secreting bile acids into the canalicular space, followed passively by water and electrolytes. Genetic mutations or acquired defects in these transporters cause intracellular retention of bile components. Intrehepatic accumulation of bile acids triggers a detergent-like cytotoxic effect on biological membranes, driving hepatocellular injury, localized inflammation, and progressive fibrotic liver disease. Physical mechanical obstructions cause similar upstream cellular damage while simultaneously starving the intestine of bile.

Clinical Presentation

• Primary Signs: Persistent jaundice, dark-coloured urine, and pale or acholic stools.
• Systemic Features: Severe pruritus (especially in older infants and children), hepatomegaly, and abdominal distension.
• Nutritional Signs: Weight loss, growth faltering, muscle wasting, and manifestations of fat-soluble vitamin deficiencies.

Diagnostic Evaluation & Workup

1. Initial Laboratory Panel

• Hepatic Profile: Total and direct/conjugated bilirubin, ALT, AST, GGT, ALP, and serum albumin.
• Coagulation & Metabolic Testing: Prothrombin time (PT)/INR, serum glucose, and basic metabolic panels.

2. Advanced & Etiology-Specific Workup

• Targeted Screening: Alpha-1 antitrypsin phenotype/levels, sweat chloride testing for cystic fibrosis, metabolic profiles, and targeted infectious disease screening (e.g., TORCH or CMV testing).
• Genetic Testing: Indicated when inherited intrahepatic cholestatic disorders (e.g., PFIC, Alagille syndrome) are suspected.

3. Imaging & Histopathology

• First-line Imaging: Abdominal ultrasonography to assess gallbladder anatomy and the biliary tree.
• Advanced Imaging: Hepatobiliary scintigraphy (HIDA scan) or magnetic resonance cholangiopancreatography (MRCP) as clinically indicated.

Invasive Interventions:

• Liver Biopsy: Evaluates the pattern, stage, and structural severity of hepatic injury.
• Operative Cholangiography: Regarded as the definitive diagnostic standard when biliary atresia or surgically correctable obstructive lesions cannot be excluded.

Nutritional Assessment Framework

Because chronic cholestasis impairs lipid and micronutrient absorption, serial nutritional assessments are an essential component of long-term medical management. Clinicians should systematically monitor:

• Growth monitoring: Frequent measurement of weight, length/height, and head circumference using standardized charts.
• Dietary Review: Detailed evaluation of daily caloric, lipid, and macronutrient intake.
• Biochemical Micronutrient Markers: Serum quantification of vitamins A, D, E, and K, alongside essential fatty acid profiles.
• Metabolic Bone Health: Monitoring for hepatic osteodystrophy via bone mineralisation indices, calcium, phosphate, and alkaline phosphatase tracking.

Management Strategies

• Etiology-Specific Therapy: Direct treatment of the primary hepatic, biliary, metabolic, or infectious disorder.
• Surgical Intervention: Timely surgical correction when anatomically indicated, such as a Kasai portoenterostomy for biliary atresia or cyst excision.
• Nutritional Optimization: Active dietary management of fat malabsorption, often incorporating medium-chain triglycerides (MCTs) to secure sufficient caloric intake and avoid growth faltering.
• Pediatric Surveillance: Continuous anthropometric tracking of weight, length/height, and developmental milestones in infants and children.

Fat-Soluble Vitamin Repletion

Persistent cholestasis prevents normal micellar incorporation, placing patients at high risk for clinical micronutrient deficiencies:

• Surveillance: Serial quantitative monitoring of serum vitamins A, D, E, and K, alongside coagulation parameters (PT/INR).
• Targeted Supplementation: Prescription of specialized, water-miscible or micellized formulations of vitamins A, D, E, and K to enhance intestinal absorption despite bile acid deficiency.

Clinical Overview

Cystic fibrosis (CF) is an autosomal recessive, multisystem disorder caused by pathogenic variants in the CFTR gene on chromosome 7, which encodes an epithelial chloride and bicarbonate channel. Impaired CFTR function disrupts trans-epithelial ion and water transport, producing hyperviscous secretions that cause ductal obstruction, chronic inflammation, and tissue remodelling across respiratory, gastrointestinal, pancreatic, and hepatobiliary systems. Advances in new-born screening, nutritional protocols, and CFTR modulator therapies have substantially altered disease progression and clinical outcomes.

Gastrointestinal & Hepatobiliary Pathophysiology

The failure of apical chloride and bicarbonate transport induces mucosal dehydration and macromolecular protein precipitation across targeted abdominal organs:

• Pancreas: Viscous secretions inspissate within ductules, causing mechanical obstruction and ductal ectasia. Retained proenzymes undergo premature intra-acinar activation, triggering autolysis, chronic inflammation, parenchymal destruction, and fibrotic replacement. This structural loss leads to exocrine pancreatic insufficiency (EPI) and severe nutrient maldigestion.
• Intestinal Tract: Dehydrated mucosal secretions and altered mucus-gel properties impair luminal hydration and motility, predisposing patients to distal intestinal obstruction syndrome (DIOS), chronic constipation, and ileocecal impaction.
• Hepatobiliary Tree: Defective CFTR in cholangiocytes prevents fluid and bicarbonate secretion, yielding stagnant, hyperviscous bile. Chronic biliary sludge causes focal ductal obstruction and localized periportal inflammation, which activates hepatic stellate cells and can drive periportal fibrosis, multilobular biliary cirrhosis, portal hypertension, and CF-associated liver disease (CFLD).

Fat Malabsorption & Clinical Manifestations

Inadequate intraluminal release of pancreatic lipase prevents the hydrolysis of dietary triglycerides into absorbable fatty acids and monoglycerides. The resulting lipid malabsorption drives systemic caloric deficits and compromises the absorption of fat-soluble vitamins (A, D, E, and K).

Diagnostic Evaluation

CF diagnosis relies on a combination of characteristic clinical features, screening findings, and documented CFTR channel dysfunction:

• Newborn Screening (NBS): Initial measurement of immunoreactive trypsinogen (IRT) from dried blood spots, followed by protocolized repeat IRT or reflex CFTR variant testing. Positive screens require definitive diagnostic confirmation.
• Sweat Chloride Test: The gold-standard functional bioassay. A quantitative pilocarpine iontophoresis sweat chloride level ≥60 mmol/L confirms CFTR dysfunction when clinically correlated. Intermediate values (30–59 mmol/L) necessitate repeat testing or advanced diagnostics.
• Molecular Genetic Testing: Comprehensive CFTR variant analysis identifies biallelic disease-causing mutations (e.g., F508del and ethnic-specific variants). It confirms diagnosis, defines phenotypic correlations, enables family counseling, and directs eligibility for targeted CFTR modulator therapies.

Management Strategies

• Enzyme Replacement: Pancreatic enzyme replacement therapy (PERT) administered with all lipid- and protein-containing meals/snacks to mitigate steatorrhoea and improve nutrient uptake.
• Nutritional Support: High-calorie, high-fat dietary strategies matched with routine fat-soluble vitamin supplementation (A, D, E, and K) adjusted to serum levels.
• Hepatobiliary Monitoring: Serial surveillance of liver function parameters, physical signs of hepatomegaly, and abdominal ultrasonography for early detection of CFLD.

Clinical Overview

Exocrine pancreatic insufficiency (EPI) is a physiological state characterised by the deficient secretion or inadequate luminal delivery of pancreatic digestive enzymes and bicarbonate. This deficiency severely compromises macronutrient hydrolysis within the small intestine.

Because pancreatic lipase is uniquely sensitive to parenchymal dysfunction and luminal acidification, lipid maldigestion is typically the earliest and most severe consequence of EPI. Unchecked fat malabsorption drives debilitating gastrointestinal symptoms, progressive weight loss, and secondary deficiencies of fat-soluble vitamins (A, D, E, and K).

Etiology & Pathophysiology

EPI arises from progressive destruction of functional pancreatic parenchyma, mechanical obstruction of the main pancreatic duct, or postsurgical disruptions of gastroduodenal synchronization.

Primary Mechanisms

• Chronic Pancreatitis: The leading cause of adult EPI. Persistent or recurrent pancreatic inflammation drives progressive parenchymal fibrosis and acinar atrophy. Lipase and bicarbonate secretion decline sequentially; structural damage eventually impairs proteolytic and amylolytic digestion.
• Cystic Fibrosis: The primary cause of pediatric EPI. Pathogenic CFTR variants disrupt apical chloride and bicarbonate transport, producing hyperviscous ductal secretions. The resulting mechanical obstruction precipitates acinar autolysis, chronic localized inflammation, and fibrotic replacement of the functional exocrine tissue.
• Other Associated Conditions: Pancreatic duct obstruction (e.g., malignancy), surgical resections (whipple procedure, total pancreatectomy), celiac disease, inflammatory bowel disease (IBD), diabetes mellitus, and postsurgical alterations of gastrointestinal anatomy.

Clinical Manifestations & Complications

The clinical presentation reflects the extent of exocrine decline, the compensatory capacity of gastric/lingual lipases, and the underlying primary pathology.

Diagnostic Strategies

Diagnostic evaluation is indicated for patients presenting with classic gastrointestinal symptoms, unexplained weight loss, or an established high-risk predisposing condition.

• Fecal Elastase-1 (FE-1): The preferred, non-invasive first-line screening assay. It utilizes monoclonal antibodies to measure human elastase-1, which remains stable during transit through the GI tract.
• <100 µg/g stool: Strongly suggestive of severe EPI.
• 100–200 µg/g stool: Indeterminate range; warrants clinical correlation or repeat testing.
• >200 µg/g stool: Normal exocrine function; EPI is less suggestive.

The 13C-mixed triglyceride breath test evaluates fat digestion by pancreatic lipase. Following ingestion of a test meal containing a ^13C-labelled triglyceride, digestion generates ^13CO₂, which is subsequently measured in exhaled breath.

• Quantitative Fecal Fat (72-Hour Collection): The historical diagnostic benchmark. It requires a strict, high-fat diet (100g daily) and total stool collection over 72 hours. Due to poor patient adherence and cumbersome handling, its routine clinical utility is limited.

Supportive Laboratory Assessment

• Micronutrient Monitoring: Quantitative serum assays for vitamins A, D, E, and K.
• Skeletal Health: Dual-energy X-ray absorptiometry (DEXA) screening to evaluate bone mineralisation indices in chronic, unmanaged states.

Management Strategies

The therapeutic framework for EPI targets the normalization of nutrient digestion, weight maintenance, and prevention of metabolic bone or micronutrient diseases.

• Pancreatic Enzyme Replacement Therapy (PERT): The definitive therapeutic intervention. Enteric-coated microspheres are administered orally with the first bite of all meals and snacks. The enteric coating prevents gastric acid inactivation, releasing active lipase, protease, and amylase directly into the alkaline environment of the duodenum.
• Dietary Strategy: Patients must avoid low-fat diets. A normal-to-high fat, calorically dense diet is encouraged to maximize absolute energy absorption, balanced dynamically by optimized PERT dosing.
• Micronutrient Intervention: Targeted supplementation with water-soluble formulations of fat-soluble vitamins (A, D, E, K) when baseline deficiencies or chronic malabsorptive risks are confirmed.
• Long-Term Monitoring: Serial evaluations of weight trajectories, physical signs of sarcopenia, compliance with PERT, and biochemical surveillance of fat-soluble vitamin levels.

Clinical Overview

Celiac disease is a chronic, systemic immune-mediated enteropathy triggered by dietary gluten ingestion (proteins found in wheat, rye, and barley) in genetically susceptible individuals. The resulting autoimmune mucosal inflammation causes blunting of the small-intestinal microvasculature and villous architecture, diminishing absorptive surface area and inducing widespread malabsorption of macronutrients, minerals, and fat-soluble vitamins (A, D, E, and K).

Etiology & Pathophysiology

Celiac disease develops through an interplay between dietary gluten exposure, genetic susceptibility, and coordinated innate and adaptive immune responses.

• Genetic Basis: Strongest association is with HLA class II alleles, specifically HLA-DQ2 and HLA-DQ8. While nearly all affected individuals carry one of these heterodimers, their presence alone is not diagnostic because they occur in a substantial portion of the healthy general population.
• Deamidation & T-Cell Activation: Ingested gluten peptides resist complete enzymatic breakdown, generating immunogenic gliadin fragments. In the lamina propria, tissue transglutaminase (tTG) deamidates these gliadin peptides, dramatically increasing their binding affinity to HLA-DQ2/DQ8 on antigen-presenting cells. This triggers CD4+ T-cell activation, proinflammatory cytokine cascade release, and downstream B-cell antibody production (tTG-IgA and EMA-IgA).
• Histopathological Injury: Lamina propria and intraepithelial cytotoxic lymphocyte recruitment damages the mucosa, resulting in a characteristic triad:
• Villous atrophy (flattening of absorptive villi).
• Crypt hyperplasia (reactive epithelial turnover).
• Increased intraepithelial lymphocytes (IELs).

Mucosal Malabsorption & Clinical Presentation

Because the proximal small intestine is the primary site of nutrient uptake, extensive enterocyte destruction compromises multiple metabolic pathways:

Diagnostic Evaluation

1. Initial Serology

• Anti-tissue Transglutaminase IgA (tTG-IgA): The preferred first-line screening bioassay due to high sensitivity and specificity.
• Total Serum IgA: Must be measured concurrently to identify selective IgA deficiency. In IgA-deficient individuals, IgG-based serologies (e.g., IgG-tTG or IgG-deamidated gliadin peptides [DGP]) should be utilized.
• Anti-endomysial Antibodies (EMA-IgA): Carries near-100 percentage specificity; serves as an exceptional confirmatory test in indeterminate or equivocal settings.

2. Small-Intestinal Biopsy

• Endoscopic Confirmation: The historical diagnostic standard in adults. Involves upper endoscopy with multiple mucosal biopsies (from the duodenal bulb and distal duodenum) demonstrating villous atrophy, crypt hyperplasia, and elevated IELs (Marsh classification).
• Pediatric Non-Biopsy Approach: Applicable in select pediatric cohorts exhibiting high-titer tTG-IgA (≥10× the upper limit of normal) verified by a positive secondary EMA-IgA from a separate blood draw, avoiding general anesthesia and endoscopy in accordance with specialized pediatric guidelines.

3. HLA-DQ2/DQ8 Genotyping

Serves primarily for its high negative predictive value (NPV). The absence of both HLA-DQ2 and HLA-DQ8 makes celiac disease virtually impossible, proving useful to exclude the diagnosis in ambiguous cases or patients already on a gluten-free diet.

Management Strategies

• Strict Lifelong Gluten-Free Diet (GFD): Complete dietary elimination of wheat, rye, barley, and contaminated derivatives. This halts immune activation, promotes mucosal healing, and resolves malabsorption.
• Nutritional Repletion: Baseline identification and aggressive supplementation of deficient micronutrients, particularly iron, folate, vitamin B₁₂, calcium, and vitamins A, D, E, and K.
• Long-Term Monitoring: Serial evaluations of dietary compliance with a specialized gastrointestinal dietitian, regular monitoring of serological titers (tTG-IgA) to assess mucosal recovery and periodic bone mineral density (DEXA) scans.
• Refractory Reassessment: In patients with non-responsive symptoms or persistent nutritional deficits, re-evaluate dietary adherence, occult gluten contamination, refractory celiac disease, or concurrent secondary malabsorptive etiologies (e.g., pancreatic insufficiency, SIBO).

Clinical Overview

Small intestinal bacterial overgrowth (SIBO) is a clinical syndrome characterised by an abnormal quantitative increase and/or taxonomic shift in the microbial population within the small bowel. Unlike the colon, which houses a dense microbial ecosystem, the small intestine maintains a low bacterial burden through an array of physiological clearative and antimicrobial barriers.

When these homeostatic defenses are compromised, proliferating bacteria ferment luminal carbohydrates and deconjugate bile salts, driving prominent gastrointestinal distress and, in severe or protracted cases, structural enterocyte irritation with subsequent malabsorption of macronutrients and fat-soluble vitamins (A, D, E, and K).

Physiological Barriers & Etiology

The restriction of microbes to the large intestine depends on the coordinated execution of multiple defense mechanisms. SIBO develops secondarily when one or more of these barriers fail:

• Gastric Acid Secretion: Eradicates ingested pathogens and limits entry into the proximal duodenum.
• Bile & Pancreatic Enzymes: Exert potent, direct antimicrobial activity while executing primary luminal digestion.

Intestinal Peristalsis & the Migrating Motor Complex (MMC): Functions as an electrochemical "housekeeper," mechanically sweeping residual contents and bacteria downstream into the colon during fasting phases.

• Anatomical Competence: An intact ileocecal valve prevents the retrograde translocation of colonic microflora into the terminal ileum.
• Mucosal Immunity: Secretory immunoglobulin a (sIgA) limits bacterial adherence and colonization along the brush border.
• Concurrent Enteropathies: Established celiac disease, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).

Pathophysiology & Clinical Manifestations

Proliferating bacteria compete with the host for nutrients and fundamentally alter the intraluminal environment. Intestinal microbes prematurely deconjugate and dehydroxylate bile acids, rendering them incapable of forming the mixed micelles necessary for lipid transport. This specific breakdown step causes progressive fat malabsorption and steatorrhoea. Additionally, bacteria consume luminal vitamin B₁₂ (cobalamin), potentially precipitating a macrocytic anemia despite adequate dietary intake.

Diagnostic Evolution

Because clinical manifestations overlap considerably with other functional and structural bowel disorders, objective diagnostic confirmation is required.

1. Non-Invasive Breath Testing

• Substrates: Utilizes standardized oral doses of glucose (absorbed in the proximal small bowel; high specificity for proximal SIBO) or lactulose (non-absorbable polysaccharide; transits the entire length of the small bowel, offering high sensitivity for distal overgrowth).
• Metrics: Measures exhaled hydrogen (H₂) and methane (CH₄) gases generated exclusively by microbial fermentation in the gut. A rise in hydrogen of ≥ 20 ppm above baseline within 90 minutes, or a methane concentration of ≥ 10 ppm at any point, is diagnostic based on consensus guidelines.

2. Small-Intestinal Aspirate and Culture

• Methodology: Direct endoscopic sampling of fluid from the distal duodenum or jejunum followed by quantitative aerobic/anaerobic cultures.
• Threshold: Growth of ≥ 10³ colony-forming units per milliliter (CFU/mL) confirms overgrowth.

3. Secondary Nutritional Panel

• Indicated for patients with confirmed SIBO and chronic diarrhoea, steatorrhoea, or weight loss:
• Complete blood count (CBC) and peripheral blood smear (surveillance for macrocytosis).
• Iron parameters, serum vitamin B₁₂, and RBC folate.
• Quantitative serum levels of vitamins A, D, E, and K.
• Serum albumin and prealbumin to evaluate systemic protein status.

Management Strategies

Therapy must simultaneously eradicate the overgrowth, manage symptoms, address the root cause, and correct metabolic deficits.

• Antimicrobial Eradication: Targeted, short-course antibiotic therapy tailored by the treating clinician. Rifaximin—a minimally absorbed, gut-selective antibiotic—remains a clinical cornerstone due to its low systemic side-effect profile and efficacy in the small intestine. For methane-dominant overgrowth, combination regimens (e.g., rifaximin plus neomycin or metronidazole) are frequently deployed.
• Address the Primary Etiology: Optimize prokinetic therapies for dysmotility, manage active celiac or Crohn's flares, replace missing enzymes in EPI, and structurally correct anatomical strictures or blind loops when feasible.
• Dietary Modulation: Short-term implementation of fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (low-FODMAP) or elementally structured diets to starve the bacterial population and reduce osmotic bloating.
• Nutritional Repletion: Parenteral or specialized oral water-soluble supplementation of vitamins A, D, E, and K, alongside intramuscular or sublingual cobalamin (B₁₂) administration to bypass altered small intestinal handling.